Physician profile
Valery Kuznetsov
NPI 1841218039
$12,738.49
in general payments reported to CMS, 2019-2025
35 companies · $2,391 in 2025
The $2,391 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $921 · 2021: $1,690 · 2022: $2,209 · 2023: $1,788 · 2024: $1,968 · 2025: $2,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,127 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,126.69 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,825.01 | 2019-2025 | |
| Amgen INC. | $1,348.13 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,224.91 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,194.93 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $916.29 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $896.21 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $833.84 | 2019-2025 | Jardiance |
| Pfizer INC. | $760.96 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $727.38 | 2020-2024 | |
| Philips North America LLC | $536.37 | 2024-2025 | Ecc Solutions, (Ck7) Extended Holter, Mcot |
| Arbor Pharmaceuticals, INC. | $397.32 | 2019-2022 | |
| Scpharmaceuticals INC. | $221.75 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.26 | 2022-2023 | |
| Glaxosmithkline, LLC. | $178.90 | 2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $164.98 | 2023-2024 | Nexletol |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $162.13 | 2019 | |
| Alnylam Pharmaceuticals INC. | $161.80 | 2025 | Amvuttra |
| Abiomed | $160.32 | 2025 | |
| Vifor Pharma, INC. | $133.80 | 2021 | |
| Genzyme Corporation | $120.47 | 2025 | |
| Heartflow, INC. | $109.65 | 2024-2025 | |
| Edwards Lifesciences Corporation | $59.28 | 2019-2020 | |
| Atricure, INC. | $48.96 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $48.40 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $47.81 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $47.53 | 2023-2024 | Inpefa |
| Medtronic, INC. | $35.17 | 2023 | Mycarelink |
| Biotronik INC. | $30.15 | 2025 | Acticor 7 Vr-T Dx |
| Abbott Laboratories | $24.92 | 2024 | Aveir |
| Kiniksa Pharmaceuticals, LTD. | $23.05 | 2023 | Arcalyst |
| Athena Bioscience, LLC | $20.69 | 2025 | Nexiclon Xr |
| Medtronic Vascular, INC. | $18.05 | 2020 | |
| Boston Scientific Corporation | $17.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.60 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.79 | 2025 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valery Kuznetsov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.